Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
6
×
fda
6
×
glaxosmithkline
6
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
indiana blog main
indiana top stories
ipo
allergan
amgen
bristol-myers squibb
cancer
crispr
duchenne muscular dystrophy
genentech
incyte
What
bio
roundup
crispr
black
days
diamond’s
drugs
moves
week
alliance
appetite
august
big
biopharma
biotech
bosley's
bosley’s
bread
bridge
bristol
bucks
busy
butter
buy
buyout
calls
cancer
cas
cash
ceo
changing
color
companies
congress
congressional
continue
crime
debut
decisions
departure
Language
unset
Current search:
glaxosmithkline
×
fda
×
" eli lilly "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More